These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10483695)

  • 1. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
    Mengs U; Witthohn K; Schwarz T; Lentzen H
    Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.
    Mengs U; Göthel D; Leng-Peschlow E
    Anticancer Res; 2002; 22(3):1399-407. PubMed ID: 12168816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
    Gabius S; Gabius HJ
    Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
    Dohmen W; Breier M; Mengs U
    Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ingredients of mistletoe (Viscum album L.) as potential drugs].
    Franz H
    Pharmazie; 1985 Feb; 40(2):97-104. PubMed ID: 3889937
    [No Abstract]   [Full Text] [Related]  

  • 6. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review.
    Bocci V
    J Biol Regul Homeost Agents; 1993; 7(1):1-6. PubMed ID: 8346712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
    Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
    Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
    Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
    Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comment on S. Gabius, H.-J. Gabius: Immune modulating mistletoe therapy by lectin standardization: a double-edged sword?].
    Wetzel D; Mengs U; Schwarz T
    Versicherungsmedizin; 2000 Mar; 52(1):38-40. PubMed ID: 10718092
    [No Abstract]   [Full Text] [Related]  

  • 10. [The mistletoe myth--claims, reality and provable perspectives].
    Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
    Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe?
    Gabius HJ; Gabius S; Joshi SS; Koch B; Schroeder M; Manzke WM; Westerhausen M
    Planta Med; 1994 Feb; 60(1):2-7. PubMed ID: 8134410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating unconventional therapies.
    Hajto T; Saller R
    CMAJ; 1998 Oct; 159(7):759; author reply 759, 761. PubMed ID: 9805018
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
    Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
    Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
    Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.
    Stauder H; Kreuser ED
    Onkologie; 2002 Aug; 25(4):374-80. PubMed ID: 12232491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.
    Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J
    Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of immunoactive mistletoe lectin-I.
    Beuth J
    Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mistletoe or not mistletoe is still the question.
    Kiene H; Büschel G; Hornebar M
    Forsch Komplementarmed Klass Naturheilkd; 2001 Oct; 8(5):309-12. PubMed ID: 11760713
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunomodulating mistletoe therapy by lectin standardization: a double-edged sword?].
    Gabius S; Gabius HJ
    Versicherungsmedizin; 1999 Sep; 51(3):128-36. PubMed ID: 10516836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
    Galanina OE; Kaltner H; Khraltsova LS; Bovin NV; Gabius HJ
    J Mol Recognit; 1997; 10(3):139-47. PubMed ID: 9408830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.